CLINICAL UPDATE · FOR HEALTHCARE PROFESSIONALS

Primary Care
Research Brief

18 September 2026

A shorter week of useful evidence: reinforce eligible RSV vaccination, reassure most families after febrile seizures, and avoid overconfidence in antibiotic-allergy scores. No new blanket prescribing rule is justified.

18 SEPTEMBER · PEER-REVIEWED OBSERVATIONAL COHORT

RSV vaccination: strong protection against severe disease in routine care

Question and result. Does RSV vaccination protect older adults outside trials? Among 14.8 million community-dwelling US Medicare adults aged 65 or older, adjusted vaccine effectiveness was 81.8% against RSV hospitalisation (95% CI 80.0–83.4) and 85.0% against RSV-related death (75.1–90.9) in the 2023–2024 season.

Evidence and limitations. Moderate-strength observational evidence with clinical outcomes and exceptional size. Administrative coding and residual healthy-vaccinee confounding remain concerns. It covers one season and excludes important groups including care-home residents and dialysis patients. It cannot establish product superiority or revaccination intervals.

GP implication. Check vaccination status in eligible older patients and address missed opportunities. Eligibility, funding and availability differ between South Africa, the UK and Ireland; use the current local programme rather than importing US age criteria.

Verdict: Strengthen delivery now where eligible; keep eligibility and dosing policy unchanged.

Read the RSV effectiveness study →

14 SEPTEMBER · PEER-REVIEWED NATIONAL REGISTRY COHORT

Febrile seizures: reassuring long-term learning outcomes for most children

Question and result. Are childhood febrile seizures associated with poorer school performance? Among 672,119 Danish children, the adjusted difference was only −0.4 points on a 1–100 test-score scale (95% CI −0.7 to −0.2). A single hospital contact showed no clear difference; seven or more contacts were associated with a larger deficit of −5.8 points.

Evidence and limitations. Moderate-strength longitudinal evidence, supported by sibling comparisons. Hospital records did not reliably separate simple from complex seizures; children without school tests were excluded. Familial and neurodevelopmental confounding remains possible. Associations in recurrent seizures or later epilepsy do not prove seizure-induced damage.

GP implication. Reassure families that most children are unlikely to have clinically meaningful learning impairment. Respond to developmental or school concerns, especially with recurrent seizures or later epilepsy, rather than arranging blanket additional investigations.

Verdict: Treatment unchanged; more confident counselling and targeted follow-up.

Read the febrile-seizure cohort →

16 SEPTEMBER · PEER-REVIEWED DIAGNOSTIC VALIDATION LETTER

Cephalosporin allergy scores are not a stand-alone licence to delabel

Question and result. Can history-based scores identify patients suitable for allergy testing? In a US tertiary-clinic cohort of 121 adults, 23 had confirmed allergy. Among patients classified as low risk, positive testing occurred in 5/87 with CEPH-FAST and 3/78 with the Vanderbilt tool; negative predictive values were 94.3% and 96.2%, respectively.

Evidence and limitations. Low-certainty evidence: small retrospective external validation, predominantly White women, selected referral population, uncertain skin-test accuracy and wide confidence intervals. This was not a trial showing safe GP-led delabelling.

GP implication. Record the culprit drug, route, timing and reaction severity. Use a supervised local allergy pathway rather than removing a label or recommending an unsupervised challenge from a score alone.

Verdict: Watch the tools; existing safe allergy assessment remains unchanged.

Read the allergy-tool validation →

MOST WORTH READING · RANKED

Three primary papers

Window: 12–18 September 2026. All selected papers are peer-reviewed; no preprints or conference-only findings are included. No verified major local guideline update is included this week. Some publisher and guideline pages were inaccessible, so coverage is not exhaustive. Educational summary for healthcare professionals; local guidance and individual assessment take precedence.

Earlier briefings: 11 September · 4 September.